NCT02182596 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML (MYLOFRANCE2) (NCT02182596)

Trial Description
For several years, the effective standard induction chemotherapy for Acute Myeloid Leukemia (AML) has been limited to the association of anthracycline and aracytine. The antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) is the first effective targeted antibody used in leukemia patients. In a previous study, we showed efficacy and safety of fractionated doses of gemtuzumab ozogamicin (GO) used as a single agent for treatment of adult AML patients in first relapse. In the present study the possibility of combining fractionated doses of gemtuzumab ozogamicin to escalated doses of a 3+7 regimen old is studied in relapsed AML patients > 50 and <70 years.

This trial is sponsored by Acute Leukemia French Association (ALFA). [1]

Study Data

  • Condition: Acute Myeloid Leukemia
  • Interventions:
  • Phase: I & II
  • Enrollment: 20
  • Start: June 2006
  • Completion: January 2011
  • Last verified: July 2014

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 21, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.